Airway stents: a retrospective evaluation of indications, results and complications: In our 10-year experience

M. Özgül, E. Çetinkaya, E. Seyhan, D. Tutar, Efsun Uğur, Güler Özgül, D. Doğan
{"title":"Airway stents: a retrospective evaluation of indications, results and complications: In our 10-year experience","authors":"M. Özgül, E. Çetinkaya, E. Seyhan, D. Tutar, Efsun Uğur, Güler Özgül, D. Doğan","doi":"10.1183/13993003.congress-2019.pa4801","DOIUrl":null,"url":null,"abstract":"Background: Tracheobronchial stents (TBS) are the principal modality used to manage intrinsic tracheobronchial pathology and extrinsic airway compression. Objectives: To assess the placement, indications, surveillance management, complications, and long-term outcomes of the TBS managed by rijid endoscopy (RB) in our 10-year experience. Methods: The medical records of all patients who underwent TBS insertion in our center from Novenber 2008 to September 2018 were reviewed for background data, underlying diseases, symptoms, treatment, stent indications, complications and outcome. Results: A total of 305 patients received 340 TBS. TST were placed in patients with malignant (n = 223) and benign airway diseases (n = 82). Stents were in place for a median duration of 88 (34-280) days in patients with malignancies and 775 (228-2085) days in patients with benign diseases. There was no stent-related mortality. Mucostasis (19 %) and granulation tissue formation (17 %) were the most common stent‑related complications. Type of benign disease, the presence of metastatic tracheobronchial tumors, lenght of time past stent implantation and the shape of the stent were associated with development of complications. The 5-year survival rate was 70% for patients with bening diseases and 19% for patients with malignant diseases. Conclusions: TST offer a safe and effective therapy for patients who benign and malignant tracheobronchial pathology.","PeriodicalId":93455,"journal":{"name":"Interventional pulmonology (Middletown, Del.)","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventional pulmonology (Middletown, Del.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/13993003.congress-2019.pa4801","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tracheobronchial stents (TBS) are the principal modality used to manage intrinsic tracheobronchial pathology and extrinsic airway compression. Objectives: To assess the placement, indications, surveillance management, complications, and long-term outcomes of the TBS managed by rijid endoscopy (RB) in our 10-year experience. Methods: The medical records of all patients who underwent TBS insertion in our center from Novenber 2008 to September 2018 were reviewed for background data, underlying diseases, symptoms, treatment, stent indications, complications and outcome. Results: A total of 305 patients received 340 TBS. TST were placed in patients with malignant (n = 223) and benign airway diseases (n = 82). Stents were in place for a median duration of 88 (34-280) days in patients with malignancies and 775 (228-2085) days in patients with benign diseases. There was no stent-related mortality. Mucostasis (19 %) and granulation tissue formation (17 %) were the most common stent‑related complications. Type of benign disease, the presence of metastatic tracheobronchial tumors, lenght of time past stent implantation and the shape of the stent were associated with development of complications. The 5-year survival rate was 70% for patients with bening diseases and 19% for patients with malignant diseases. Conclusions: TST offer a safe and effective therapy for patients who benign and malignant tracheobronchial pathology.
气道支架:回顾性评估适应症,结果和并发症:在我们10年的经验
背景:气管支气管支架(TBS)是治疗内源性气管支气管病理和外源性气道压迫的主要方式。目的:在我们10年的经验中,评估刚性内窥镜(RB)治疗TBS的位置、适应症、监测管理、并发症和长期结果。方法:回顾2008年11月至2018年9月在我中心接受TBS置入的所有患者的病历,包括背景资料、基础疾病、症状、治疗、支架适应证、并发症和转归。结果:305例患者共接受340例TBS治疗。将TST放置于恶性(n = 223)和良性气道疾病(n = 82)患者。恶性肿瘤患者支架放置的中位时间为88(34-280)天,良性疾病患者支架放置的中位时间为775(228-2085)天。没有与支架相关的死亡率。粘膜凝固(19%)和肉芽组织形成(17%)是最常见的支架相关并发症。良性疾病的类型、转移性气管支气管肿瘤的存在、支架植入时间的长短和支架的形状与并发症的发生有关。良性疾病患者5年生存率为70%,恶性疾病患者5年生存率为19%。结论:TST治疗气管支气管良恶性病变是一种安全有效的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信